Purchase Order 75N91019P00151

<p>The National Cancer Institute awarded a purchase order to Genus Biosystems Inc. for $57,564.00 on September 17, 2018. The order, which carried no set-aside designation, covers exploration of gene expression and microRNA expression changes in tumors exposed to radiation, with and without specified treatment modalities. Work is performed in Northbrook, Illinois. The order is firm fixed price and carries an ultimate completion date of September 16, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genus Biosystems Inc. valued at $57,268.80 on August 3, 2018, to test radiation-induced mRNAs in a mini pig model and determine whether these mRNAs can be used as organ-specific markers at various doses and time points. No set-aside applied. Work is performed in Northbrook, Illinois. The order is firm fixed price with an ultimate completion date of August 2, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genus Biosystems Inc. valued at $38,179.20 on September 19, 2019. No set-aside was used. Work is performed in Northbrook, Illinois. The order is firm fixed price with an ultimate completion date of January 19, 2020. The solicitation was posted August 22, 2019 as a Special Notice with a due date of August 28, 2019.</p>

This firm fixed price purchase order, awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute, is for $37,785.60 in mRNA and microRNA microarray profiling services to support the prediction of radiation therapy outcomes. The prime contractor is Genus Biosystems Inc., located in Northbrook, Illinois, and no set-aside designation was applied to this procurement. The contract completion date is August 19, 2024, suggesting the National Cancer...

<p>The National Cancer Institute issued a purchase order to Genus Biosystems Inc. valued at $14,287.68 on September 15, 2017, with completion by October 31, 2017. Work is performed in Northbrook, Illinois. No set-aside applies. The order procures laboratory testing services in genomics and transcriptomics to support cancer research.</p>

<p>The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a firm fixed-price purchase order to Genus Biosystems Inc., a for-profit organization, for $23,520.00 to provide lab testing services. The contract has a completion date of November 1, 2024 and was awarded on May 1, 2024. The place of performance is Northbrook, IL 60062, USA. This contract award is not associated with any set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Biospace Lab USA, Inc. for $21,004.00 on February 26, 2020, with an ultimate completion date of March 7, 2021. The order is for photon imager services, performed at Columbia, Maryland. Pricing is firm fixed price with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Bio-Rad Laboratories, Inc. valued at $37,499.00 on August 18, 2026, for laboratory research supplies supporting protein expression visualization and evaluation in lung cancer research.</p> <p>Place of performance is Bethesda, Maryland. The order carries a firm fixed-price structure with ultimate completion by August 17, 2027. No small business set-aside applies.</p>

<p>The National Cancer Institute awarded a purchase order to 10X Genomics, Inc. for $5,850.00 on March 15, 2018, with ultimate completion on April 13, 2018. The order covers laboratory supplies under firm fixed price terms. Place of performance is Pleasanton, California.</p>

<p>The National Cancer Institute issued a purchase order to Gene Square Bio-Technology LTD. for $114,966.00 on September 16, 2019, for genetic studies of myeloid and lymphoid malignancy in China. Work is performed in China. The order is firm fixed price with an ultimate completion date of September 15, 2020. The requirement originated from a special notice posted July 23, 2019, with a due date of July 31, 2019.</p>